SCHEMBL1320154

SCHEMBL1320154

O=C(Cc1ccccc1)Nc1nc2ccc(F)cn2c1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 1/20 0.47
RET P07949 1/20 0.44
CSNK1D P48730 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
KDM4E B2RXH2 2/20 0.43
XBP1 P17861 1/20 0.43
ALOX12 P18054 1/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PDE5A O76074 1/20 0.41
P2RY14 Q15391 1/20 0.41
ORAI1 Q96D31 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
KCNQ2 O43526 1/20 0.41
BACE1 P56817 1/20 0.40
CXCR2 P25025 1/20 0.40
MAPK14 Q16539 1/20 0.40
NR2E1 Q9Y466 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1320653 0.95 RET (0.47) MEN1KMT2AMAPTRETCSNK1D
SCHEMBL1320095 0.89 MAPK14 (0.48) MEN1KMT2AMAPTRETCSNK1D
SCHEMBL1320928 0.88 MAPK14 (0.49) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1322413 0.87 TRPA1 (0.39) MAPTRETCSNK1DKDM4EALDH1A1
SCHEMBL1320400 0.87 RET (0.44) MEN1KMT2AMAPTRETKDM4E
SCHEMBL1319654 0.87 HDAC1 (0.40) MAPTRETKDM4EALDH1A1
SCHEMBL1320242 0.87 SMN1; SMN2 (0.44) MEN1KMT2ARETCSNK1DKDM4E
SCHEMBL1319402 0.86 P2RY14 (0.47) RETCSNK1DSMN1; SMN2P2RY14MAPK14
SCHEMBL1321100 0.86 CSNK1D (0.41) MAPTCSNK1DKDM4EALDH1A1SMN1; SMN2
SCHEMBL1320178 0.85 MAPK14 (0.44) RETCSNK1DSMN1; SMN2P2RY14MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018208-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2015-04-28 US disclosed
US-20130143889-A1 Heterocycles As Potassium Channel Modulators ICAGEN INC. (US) 2013-06-06 US disclosed
US-8431608-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2013-04-30 US disclosed
US-8058274-B2 Heterocycles as potassium channel modulators ICAGEN, INC. (US) 2011-11-15 US disclosed
US-20100240663-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-09-23 US disclosed
EP-2178373-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2010-04-28 EP disclosed
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-03-05 US disclosed
WO-2009026254-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143889-A1 Heterocycles As Potassium Channel Modulators KCNK10, KCNK9, KCNJ2 MEN1 1013/4885KMT2A 1276/4885MAPT 136/4885
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK2, KCNK17 MEN1 866/4885KMT2A 1080/4885MAPT 106/4885
US-20100240663-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK2, KCNK17 MEN1 866/4885KMT2A 1080/4885MAPT 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.